LUCIUS ANNAEUS SENECA (Minor)
OUR MISSION
OUR VISION
TARGET
INVESTMENT
SCENARIOS
SERVICES
Development of therapies specifically directed against tumor cells is possible if the therapeutic target is present only in cancer cells.
The quick realization of this goal may take place, among others, due to the investment in Personather company and its project (intermediate preclinical trials). One of the project has funding from the NCRD - National Centre for Research and Development.
Implementation of own pre-clinical tests by Personather. Additional projects implementation.
Company carries out service and sales activities. Instant income.
KEY INFORMATION
OUR PROJECTS
Project “Development of anticancer targeted therapy based on small molecules regulating mutated RAS protein G12V” is co-funded by the European Regional Development Fund under the Operational Programme Smart Growth 2014 - 2020.
Project value - 5,979,640.00 PLN,
Eligible expenses - 5,979,640.00 PLN,
Value of EU funding - 4,531,314.95 PLN
OUR SERVICES
OUR PRODUCTS
MANAGEMENT TEAM
Prof. Piotr Rieske
Chairmam of the board Personather Ltd., CTO, Shareholder
In 2008 prof. Rieske was one of the founders of biotech company Celther Polska Ltd, where he currently helds the CTO position. He participated in several commercializations (stem cells technologies, biodegradable bandage, many scientific research tools). In 2016, he founded the Personather Ltd. Prof. Piotr Rieske gained his PhD in 1998, two years after getting MSc. He took part in postdoctoral internship at the Thomas Jefferson University, Hahnemann University Hospital and Temple University in Philadelphia. In Poland he was involved in cancer molecular biology research. Since 2012, he is the Chief of Department of Tumor Biology at the Medical University of Lodz. In 2013, he was awarded full professorship. Prof. Rieske is an author of 66 scientific publications, 4 patents and 17 patent applications (involving seven new anticancer therapies). |
|
Ewelina Stoczynska-Fidelus
PhD, hab. Shareholder, cellular/molecular biologist
Ewelina graduated from Molecular Genetics at the University of Lodz, Poland and gained her PhD in the Department of Tumor Biology at the Medical University of Lodz, where she currently helds the position of adjunct (associate professor). During her PhD she took part in scientific fellowship at the Temple University in Philadelphia (USA) and was distinguished in the third edition of Polish Scientific Foundation scholarship programme for PhD students.
In 2015, she co-founded Personather Ltd., biotech company, where currently she is a Project Scientific Manager. Ewelina is the author of 29 scientific publications, 17 patent applications and 4 patents. She specializes in molecular oncology. |
SCIENTIFIC TEAM
OUR AWARDS
It's our great pleasure and privilege to announce that during the Central European BioForum 2019 Personather received the CEBF Award (Category: Individual Award).
https://www.facebook.com/cebioforum/photos/pcb.2283503015044756/2283497038378687/?type=3&theater
YOU ARE WELCOME TO CONTACT US